
## Yu Qiao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11428908/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut, 2020, 69, 177-186.	12.1	121
2	Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene, 2018, 37, 3229-3242.	5.9	79
3	The mTORC2â€Akt1 Cascade Is Crucial for câ€Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology, 2019, 70, 1600-1613.	7.3	70
4	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2019, 25, 403-413.	7.0	56
5	Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. PLoS ONE, 2017, 12, e0184068.	2.5	35
6	Axis inhibition protein 1 (Axin1) Deletion–Induced Hepatocarcinogenesis Requires Intact βâ€Catenin but Not Notch Cascade in Mice. Hepatology, 2019, 70, 2003-2017.	7.3	33
7	Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer, 2019, 19, 343.	2.6	17
8	Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle, 2018, 17, 1496-1512.	2.6	14
9	Focal adhesion kinase activation limits efficacy of Dasatinib in câ€Myc driven hepatocellular carcinoma. Cancer Medicine, 2018, 7, 6170-6181.	2.8	11